Printer Friendly

Cingulate Therapeutics names new chief operating officer.

M2 EQUITYBITES-April 3, 2018-Cingulate Therapeutics names new chief operating officer

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilising its precision timed release drug delivery platform technology, has named Laurie A. Myers, PhD as its new chief operating officer, it was reported on Monday.

Presently, Myers served as a founding member of the Cingulate Therapeutics board of directors. She has also played key role in clinical drug development, marketing and commercialisation for global pharmaceutical companies, including Novartis, DuPont, Pfizer and Sanofi (including predecessor companies), which included leadership positions in both R&D and marketing. Myers

has been named a brand champion in the PharmaVOICE 100. She has contributed to two investor organisations, Mid Atlantic Bio Angels and Mid Atlantic Diamond Ventures, and was commercial advisor to another start-up, EpiGen Pharma.

Shane J. Schaffer, PharmD, chairman and chief executive officer of Cingulate Therapeutics, said: "I have great confidence in the value that Laurie's extensive industry knowledge, leadership experience and strategic insights bring to Cingulate. Laurie's experience in all aspects of branded pharmaceutical life cycle management from clinical drug development through commercialisation is a major asset, which will also serve useful as she helps direct the company's clinical research, and eventual commercial functions. As we bring the proprietary manufacturing operations online for clinical trials and eventual commercial scale production, having an experienced COO on board is crucial."

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 3, 2018
Words:253
Previous Article:MediciNova's liver disease drug meets primary endpoint in phase 2 clinical trial.
Next Article:PCOM School of Pharmacy appoints new dean.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |